A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

NCT06501534 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout
Hyperuricemia

Interventions

DRUG: Febuxostat
DRUG: IBI128

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.